The research on the effectiveness of Tebexerol immunoxel for the supporting treatment of TB in growth stage was done in the Vietnam National Lung Hospital from March 2013 to October 2014. Total 230 Patients which are diagnosed by the standard of National Tuberculosis Control Program participated in the research. They are 2 branches by the type of diseases: TB AFB(+) with 100 patients and extrapulmonary tuberculosis (bone and joint tuberculosis, TB multi-membrane, tubercular meningitis) with 130 patients. Study group (group A) 115 patients is used the anti TB drugs and Tebexerol immunoxel and the Control group only use the anti TB drugs (group B). The results showed that Tebexerol immunoxel has positive effectiveness in the tuberculosis treatment in the growth stage. It is also completely safe with no side effects. Patient in group A who were treated with anti-tuberculosis drugs and Tebexerol immunoxel have faster fever decrease, better weight gain, faster decrease of CRP index and lower than in the group B, higher percentage of sputum negative, the higher rate of infiltration damage, micronodular damage and fibrosis.